-
Kenya's economy faces climate change risks: World Bank
-
More Nepalis drive electric, evading global fuel shocks
-
Latecomer Japan eyes slice of rising global defence spending
-
German fertiliser makers and farmers struggle with Iran war fallout
-
OPEC+ to make first post-UAE production decision
-
Massive crowds fill Rio's Copacabana beach for Shakira concert
-
US airlines step up as Spirit winds down
-
Aviation companies step up as Spirit winds down
-
'Bookless bookstore': audio-only book shop opens in New York
-
Venezuelan protesters call government wage hike a joke
-
S&P 500, Nasdaq end at fresh records on tech earnings strength
-
Pope names former undocumented migrant as US bishop of West Virginia
-
Trump says will raise US tariffs on EU cars to 25%
-
ExxonMobil CEO sees chance of higher oil prices as earnings dip
-
After Madonna and Lady Gaga, Shakira set for Rio beach mega-gig
-
King Charles gets warm welcome in Bermuda after whirlwind US visit
-
Coe hails IOC gender testing decision
-
Baguettes take centre stage on France's Labour Day
-
Iran offers new proposal amid stalled US peace talks
-
French hub monitors Hormuz tensions from afar
-
Oil steady after wild swing, stocks diverge in thin trading
-
Chinese swimmer Sun Yang reports cyberbullying to police
-
Iran activates air defences as Trump faces congressional deadline
-
India's cows offer biogas alternative to Mideast energy crunch
-
Crude edges up after wild swing, stocks track Wall St rally
-
Formerra Appoints Matt Borowiec as Chief Commercial Officer
-
New Princess Diana documentary promises her own words
-
Oil slumps after hitting peak, US indices reach new records
-
Venezuela leader hikes minimum wage package by 26%
-
Apple earnings beat forecasts on iPhone 17 demand
-
Bangladesh signs biggest-ever plane deal for 14 Boeings
-
Musk grilled on AI profits at OpenAI trial
-
Venezuela opens arms to world with Miami-Caracas flight
-
US Congress votes to end record government shutdown
-
First direct US-Venezuela flight in years arrives in Caracas
-
Just telling nations to quit fossil fuels 'not realistic': COP31 chief
-
Trump hails 'greatest king' Charles as state visit wraps up
-
Drivers help study road-trip mystery: what became of bug splats?
-
Oil strikes 4-year peak, stocks rise
-
Iran's supreme leader defies US blockade as oil prices soar
-
White House against Anthropic expanding Mythos model access: report
-
Oil crisis fuels calls to speed up clean energy transition
-
European rocket blasts off with Amazon internet satellites
-
Nigerian airlines avert shutdown as Mideast war hikes fuel prices
-
ArcelorMittal boosts sales but profits squeezed
-
German growth beats forecast but energy shock looms
-
Air France-KLM trims 2026 outlook over Middle East war impact
-
Oil surges 7% to top $126 on Trump blockade warning
-
Volkswagen warns of more cost cuts as profits plunge
-
Rolls-Royce confident on profits despite Mideast war disruption
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
L.K.Baumgartner--CPN